Public Law 113–260
113th Congress

An Act

To amend the Controlled Substances Act to more effectively regulate anabolic steroids.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Designer Anabolic Steroid Control Act of 2014”.

SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.

(a) DEFINITIONS.—Section 102(41) of the Controlled Substances Act (21 U.S.C. 802(41)) is amended—

(1) in subparagraph (A)—

(A) in clause (xlix), by striking “and” at the end;

(B) by redesignating clause (xlx) as clause (lxxv); and

(C) by inserting after clause (xlix) the following:

“(l) 5α-Androstan-3,6,17-trione;

“(li) 6-bromo-androstan-3,17-dione;

“(lii) 6-bromo-androsta-1,4-diene-3,17-dione;

“(liii) 4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;

“(liv) 4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;

“(lv) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3-one;

“(lvi) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;

“(lvii) 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;

“(lviii) 2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-ol;

“(lix) 2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-ol;

“(lx) 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;

“(lxi) 3β-hydroxy-estr-4,9,11-atrien-17-one;

“(lxii) 17α-methyl-androst-2-ene-3,17β-diol;

“(lxiii) 17α-methyl-androsta-1,4-diene-3,17β-diol;

“(lxiv) 17α-methyl-androsta-1,4,9,11-triene-3,17-dione;

“(lxv) 17α-methyl-androsta-1,4-diene-3,17β-diol;

“(lxvi) 18α-Homo-3-hydroxy-estr-2,5(10)-dien-17-one;

“(lxvii) 6α-Methyl-androst-4-ene-3,17-dione;

“(lxviii) 17α-Methyl-androst-5-ene-3,17-dione;

“(lxix) 17α-Methyl-5α-androstan-17β-ol;

“(lxx) 17β-Hydroxy-androstano[2,3-d]isoxazole;

“(lxxi) 17β-Hydroxy-androstano[3,2-c]isoxazole;

“(lxxii) 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazolo-5α-androstan-17β-ol;

“(lxxiii) 3,2-c]pyrazolo-androst-4-en-17β-ol;

“(lxxiv) 3,2-c]pyrazolo-5α-androstan-17β-ol; and

(2) by adding at the end the following:

(2) by adding the following:

“(2) In clause (l), by striking “and” at the end;

“(B) by redesignating clause (lxxv) as clause (lxxvi); and

“(C) by inserting after clause (l) the following:

“(i) 5α-Androstan-3,6,17-trione;

“(ii) 6-bromo-androstan-3,17-dione;

“(iii) 6-bromo-androsta-1,4-diene-3,17-dione;

“(iv) 4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;

“(v) 4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;

“(vi) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3-one;

“(vii) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;

“(viii) 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;

“(ix) 2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-ol;

“(x) 2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-ol;

“(xi) 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;

“(xii) 3β-hydroxy-estr-4,9,11-atrien-17-one;

“(xiii) 17α-methyl-androst-2-ene-3,17β-diol;

“(xiv) 17α-methyl-androsta-1,4-diene-3,17β-diol;

“(xv) Estra-4,9,11-triene-3,17-dione;

“(xvi) 18α-Homo-3-hydroxy-estr-2,5(10)-dien-17-one;

“(xvii) 6α-Methyl-androst-4-ene-3,17-dione;

“(xviii) 17α-Methyl-androst-5-ene-3,17-dione;

“(xix) 17α-Methyl-5α-androstan-17β-ol;

“(xx) 17β-Hydroxy-androstano[2,3-d]isoxazole;

“(xxi) 17β-Hydroxy-androstano[3,2-c]isoxazole;

“(xxii) 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazolo-5α-androstan-17β-ol; and

“(xxiii) 3,2-c]pyrazolo-androst-4-en-17β-ol;

“(xxiv) 3,2-c]pyrazolo-5α-androstan-17β-ol; and”;

and
“(C)(i) Subject to clause (ii), a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in subparagraph (A) and is derived from, or has a chemical structure substantially similar to, 1 or more anabolic steroids listed in subparagraph (A) shall be considered to be an anabolic steroid for purposes of this Act if—

“(I) the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either—

“(aa) promotes muscle growth; or

“(bb) otherwise causes a pharmacological effect similar to that of testosterone; or

“(II) the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone.

“(ii) A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it—

“(I) is—

“(aa) an herb or other botanical;

“(bb) a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or

“(cc) a combination of 2 or more substances described in item (aa) or (bb);

“(II) is a dietary ingredient for purposes of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.); and

“(III) is not anabolic or androgenic.

“(iii) In accordance with section 515(a), any person claiming the benefit of an exemption or exception under clause (ii) shall bear the burden of going forward with the evidence with respect to such exemption or exception.”.

(b) CLASSIFICATION AUTHORITY.—Section 201 of the Controlled Substances Act (21 U.S.C. 811) is amended by adding at the end the following:

“(i) TEMPORARY AND PERMANENT SCHEDULING OF RECENTLY EMERGED ANABOLIC STEROIDS.—

“(1) The Attorney General may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the Attorney General finds that—

“(A) the drug or other substance satisfies the criteria for being considered an anabolic steroid under section 102(41) but is not listed in that section or by regulation of the Attorney General as being an anabolic steroid; and

“(B) adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.

“(2) An order issued under paragraph (1) shall not take effect until 30 days after the date of the publication by the Attorney General of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the Attorney General may, during the pendency of proceedings under paragraph (6), extend the temporary scheduling order for up to 6 months.
“(3) The Attorney General shall transmit notice of an order proposed to be issued under paragraph (1) to the Secretary of Health and Human Services. In issuing an order under paragraph (1), the Attorney General shall take into consideration any comments submitted by the Secretary in response to a notice transmitted pursuant to this paragraph.

“(4) A temporary scheduling order issued under paragraph (1) shall be vacated upon the issuance of a permanent scheduling order under paragraph (6).

“(5) An order issued under paragraph (1) is not subject to judicial review.

“(6) The Attorney General may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under section 102(41). Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under paragraph (1).”.

SEC. 3. LABELING REQUIREMENTS.

(a) IN GENERAL.—Section 305 of the Controlled Substances Act (21 U.S.C. 825) is amended by adding at the end the following:

“(e) FALSE LABELING OF ANABOLIC STEROIDS.—

“(1) It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).

“(2)(A) A product described in subparagraph (B) is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the Federal Food, Drug, and Cosmetic Act.

“(B) A product is described in this subparagraph if the product—

“(i) is the subject of an approved application as described in section 505(b) or (j) of the Federal Food, Drug, and Cosmetic Act; or

“(ii) is exempt from the provisions of section 505 of such Act relating to new drugs because—

“(I) it is intended solely for investigational use as described in section 505(i) of such Act; and

“(II) such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.”.

(b) CLARIFICATION TO IMPORT AND EXPORT STATUTE.—Section 1010 of the Controlled Substances Import and Export Act (21 U.S.C. 960) is amended, in subsection (a)(1), by inserting “305,” before “1002”.

(c) CIVIL PENALTIES.—Section 402 of the Controlled Substances Act (21 U.S.C. 842) is amended—

(1) in subsection (a)—

(A) in paragraph (14), by striking “or” at the end;

(B) in paragraph (15), by striking the period at the end and inserting “; or”; and
(C) by inserting, after paragraph (15), the following:
“(16) to violate subsection (e) of section 825 of this title.”; and

(2) in subsection (c)(1)—
(A) by inserting, in subparagraph (A), after “subpara-
graph (B)” the following: “, (C), or (D)”;
and
(B) by inserting after subparagraph (B) the following:
“(C) In the case of a violation of paragraph (16) of subsection
(a) of this section by an importer, exporter, manufacturer, or dis-
tributor (other than as provided in subparagraph (D)), up to
$500,000 per violation. For purposes of this subparagraph, a viola-
tion is defined as each instance of importation, exportation, manu-
facturing, distribution, or possession with intent to manufacture
or distribute, in violation of paragraph (16) of subsection (a).
“(D) In the case of a distribution, dispensing, or possession
with intent to distribute or dispense in violation of paragraph
(16) of subsection (a) of this section at the retail level, up to
$1000 per violation. For purposes of this paragraph, the term ‘at
the retail level’ refers to products sold, or held for sale, directly
to the consumer for personal use. Each package, container or other
separate unit containing an anabolic steroid that is distributed,
dispensed, or possessed with intent to distribute or dispense at
the retail level in violation of such paragraph (16) of subsection
(a) shall be considered a separate violation.”.

SEC. 4. IDENTIFICATION AND PUBLICATION OF LIST OF PRODUCTS
CONTAINING ANABOLIC STEROIDS.

(a) In General.—The Attorney General may, in the Attorney
General’s discretion, collect data and analyze products to determine
whether they contain anabolic steroids and are properly labeled
in accordance with this Act and the amendments made by this
Act. The Attorney General may publish in the Federal Register
or on the website of the Drug Enforcement Administration a list
of products which the Attorney General has determined, based
on substantial evidence, contain an anabolic steroid and are not
labeled in accordance with this Act and the amendments made
by this Act.
(b) ABSENCE FROM LIST.—The absence of a product from the list referred to in subsection (a) shall not constitute evidence that the product does not contain an anabolic steroid.

Approved December 18, 2014.